RE:RE:in the NRStaghorn69 wrote: mitch0french wrote: «Prometic also intends to initiate a second phase 2/3 placebo-controlled trial which would enroll IPF patients who have failed to tolerate nintedanib or pirfenidone.»
I think this part is also interesting.
If you go to the blogs of some organism about IPF , you can see that 90% of the talks in those blogs is about the sides effects of the 2 drugs and that the patients switch from one to the other to try to tolerate the sides effects.
Those patients will choose at first, the results on there immediate wealth from the first days , well before the long term results , it's natural .What i see from those blogs is that pbi4050 can became the choice for those already in bad condition.
Or maybe, people choose 4050 FIRST given the tolerance profile....? You're already sick, do you want to try medicine #1 or #2 that will make you even more sick, or #3 that has virtually no reported side effects and may actually IMPROVE lung function.... Unlike the other two options... I like where this is going.
I'll add this - if - IF - 4050 can show it really improves treatment with nintedanib, we have a great complimentary therapy that will garner some interest from BI so it controls the tag team therapy. If 4050 ON ITS OWN is the better treatment, then it's another whole ball game. THAT is the billion dollar question! I am very pleased that there is a 4050 ONLY wing to this trial - that's where the big money will lie.